Xeris Biopharma Holdings, Inc. revises revenue guidance for the full year 2023. For the year, the company tightening revenue guidance from $155 million - $165 million to $160 million - $165 million, which is at the high end of company's original range.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.9 USD | +0.53% | +1.06% | -19.15% |
05-09 | Transcript : Xeris Biopharma Holdings, Inc., Q1 2024 Earnings Call, May 09, 2024 | |
05-09 | Earnings Flash (XERS) XERIS BIOPHARMA HOLDINGS Reports Q1 Revenue $40.6M, vs. Street Est of $41.8M | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-19.15% | 280M | |
+31.06% | 682B | |
+30.35% | 586B | |
-3.42% | 364B | |
+18.02% | 327B | |
+4.27% | 285B | |
+15.53% | 240B | |
+10.16% | 209B | |
-8.14% | 203B | |
+8.12% | 165B |
- Stock Market
- Equities
- XERS Stock
- News Xeris Biopharma Holdings, Inc.
- Xeris Biopharma Holdings, Inc. Revises Revenue Guidance for the Full Year 2023